Vermillion Shareholders Approve Reverse Stock Split | GenomeWeb

NEW YORK (GenomeWeb News) – The shareholders of Vermillion have approved a 10 for one reverse stock split of the firm’s common shares.

The reverse split is scheduled to become effective at the close of business on March 3, the Fremont, Calif.-based firm said in a statement after the close of the market on Friday. Each ten shares of Vermillion common stock will be converted into one share under the plan, which will simultaneously increase the company’s stock price by a factor of 10.

Vermillion’s shares closed Friday at $.41 on the Nasdaq.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.